Clinical Trial Detail

NCT ID NCT04305054
Title Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

MK-7684 + Pembrolizumab

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.